AAP Updates Immunization Schedule for Children and Adolescents
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: seekingalpha
- Immunization Schedule Update: The American Academy of Pediatrics (AAP) has updated its immunization schedule for children and adolescents to recommend COVID-19 and flu vaccines, contradicting CDC guidelines, which may create confusion among parents and healthcare providers.
- CDC Guideline Changes: In January, the CDC formally revised its guidelines, reducing the number of routine vaccines recommended for children and adolescents from 17 to 11, excluding COVID and flu vaccines, which could impact vaccination rates.
- Vaccination Age Adjustment: AAP recommends administering COVID and flu vaccines starting at six months old, which may increase vaccination rates, especially as flu season approaches, addressing public health concerns.
- Vaccine Manufacturer Overview: Currently, Moderna, Pfizer/BioNTech, and Novavax manufacture COVID vaccines, while Sanofi, GSK, and CSL Seqirus produce flu vaccines, highlighting the diversity and competitiveness of the vaccine market.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 29.36 USD with a low forecast of 17.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
1 Buy
14 Hold
4 Sell
Hold
Current: 47.990
Low
17.00
Averages
29.36
High
63.00
Current: 47.990
Low
17.00
Averages
29.36
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
